Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Eli Lilly (LLY) stock jumps as the company raised its full-year outlook alongside better-than-expected Q1 2026 financials ...

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest ...

CNBC’s Angelica Peebles and Eli Lilly CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

Eli Lilly confirms counterfeit Mounjaro products seized in Haryana, urging consumers to purchase only from authorized ...

Pharma major says seized fake Mounjaro in Gurugram did not originate from its supply chain, urges vigilance and purchase only ...

Eli Lilly beats Q1 estimates and raises 2026 revenue outlook to $82–$85 billion. Mounjaro and Zepbound drive strong sales ...

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

Eli Lilly responds to the recent crackdown on counterfeit Mounjaro injections in Gurugram, emphasizing patient safety and the ...